CRH Develops Wind Farm to Power Cement Plant in Romania
1.11.2024 17:15:00 EET | Business Wire | Press release
CRH (NYSE: CRH), the leading provider of building materials solutions, has developed a new wind farm to provide renewable electricity to its Medgidia Cement Plant in Romania. The wind farm is the first of its kind in the country to exclusively power a cement plant. It will meet a significant proportion of the Medgidia Plant’s annual energy requirements, helping to lower the carbon footprint of the products it produces, while also contributing to Romania’s clean energy transition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101943296/en/
(Photo: Business Wire)
Eunice Heath, Chief Sustainability Officer, CRH, said: “This is a significant clean energy project for CRH and is one of the many ways we are helping to create a more resilient and sustainable built environment. Building a wind farm to power one of our cement plants demonstrates our commitment to decarbonizing and providing lower carbon building materials solutions for our customers to help meet the changing needs of construction.”
CRH is actively investing in clean energy to help it provide lower-carbon products and solutions for its customers. By increasing its use of renewable energy sources such as wind and solar at its operations and generating renewable electricity on-site, CRH is taking an important step toward delivering its industry-leading target to reduce absolute carbon emissions by 30% by 2030.
The project commenced in August 2023 and the wind farm is now fully operational. Consisting of five turbines, it has a total installed capacity of approximately 30 MW and an estimated annual net production of 80 GWh. It will help reduce Romania's national energy related CO2 emissions by 40,000 tons.
About CRH
CRH (NYSE: CRH, LSE: CRH) is the leading provider of building materials solutions that build, connect and improve our world. Employing c.78,500 people at c.3,390 operating locations in 28 countries, CRH has market leadership positions in both North America and Europe. As the essential partner for transportation and critical utility infrastructure projects, complex non-residential construction and outdoor living solutions, CRH’s unique offering of materials, products and value-added services helps to deliver a more resilient and sustainable built environment. The company is ranked among sector leaders by Environmental, Social and Governance (ESG) rating agencies. A Fortune 500 company, CRH’s shares are listed on the NYSE and LSE. For more information visit: www.crh.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101943296/en/
Contacts
media@crh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 19:00:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research report found that leaders cited the disconnect between planning and execution as the biggest barrier to reinventing their businesses, and VentureBeat Intelligence found that 64% of res
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 19:00:00 EET | Press release
SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstration. Thales Alenia Space supported system assembly, integration, testing and operation
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom